Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank71
3Y CAGR-7.4%
5Y CAGR+8.4%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-7.4%/yr
vs +25.4%/yr prior
5Y CAGR
+8.4%/yr
Recent deceleration
Acceleration
-32.8pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$22.88M-55.8%
2024$51.78M+32.9%
2023$38.96M+35.2%
2022$28.81M+19.4%
2021$24.13M+57.8%
2020$15.29M+9.3%
2019$13.99M+20.0%
2018$11.66M-14.3%
2017$13.60M+43.9%
2016$9.45M-